NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Stockholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Big pharma steps up push for taxpayer-funded weight-loss drugs
Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Crikey5d
The company behind Ozempic is turning weight loss into massive profits
Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.
ConsumerAffairs2d
Weight loss drugs may be linked to serious eye conditions, study suggests
Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...
Ozempic competitors show there’s much to gain in weight loss drugs
Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.